Vitamin D deficiency is a prevalent and important health issue that warrants vigilant systematic screening and appropriate treatment and follow-up on the part of physicians,especially those in the primary care and cardiovascular fields. In this article we review the sources and metabolism of vitamin D, the epidemiology of vitamin D deficiency, and the available evidence linking vitamin D deficiency to cardiovascular disease; and we suggest an approach to systematic screening and to treatment of vitamin D deficiency.
Current evidence for the management and early treatment of transient ischaemic attack
Transient ischaemic attack (TIA) is an important risk factor for stroke. Early recognition of symptoms and timely secondary prevention significantly reduce stroke risk. We review current evidence and guidelines for early management and treatment of TIA, including early antiplatelet therapy, specialist review, and recognition and treatment of other risk factors. The roles of carotid artery and brain imaging are also considered.
Screening for asymptomatic atrial fibrillation at seasonal influenza vaccination
Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice. Its incidence rises with age: in the over-65s the prevalence is 4% but this rises to 8.8% in the over-80s. The prevalence of AF is on the rise due, in part, to an ageing general population and to increased longevity resulting from improved medical care. AF is clinically important because it contributes to the incidence of heart failure, stroke and overall cardiovascular mortality. In addition, when strokes occur in association with AF, patients suffer substantial mortality, disability and longer hospital stays compared to stroke patients without AF, leading to an increased financial and resource burden on the NHS.
Cardiovascular disease and diabetes in people with severe mental illness: causes, consequences and pragmatic management
The prevalence of many physical illnesses is increased in people with severe mental illness and accounts for around three quarters of all deaths; cardiovascular disease is the commonest cause of death. The level of screening for and management of diabetes and cardiovascular risk factors remains low but a straightforward yet systematic care pathway should go a long way towards reducing the health inequalities experienced by people with severe mental illness.
Key clinical points for the management of erectile dysfunction
Erectile dysfunction (ED) is a marker for cardiovascular disease, and it represents an opportunity for the clinician to intervene and reduce the patient’s cardiovascular risk. This article provides guidance on taking a history, investigations and treatments, all timely now that ED has been added to the Quality and Outcomes Framework (QOF) for 2013.
Recognition of post-stroke depression: a chance to improve outcomes
Depression is common after a stroke. All stroke patients should have their mood assessed. A range of evidence-based interventions may be used, and guidelines should be implemented since failure to treat depression leads to poorer outcomes in rehabilitation and recovery.
Retinal artery occlusion as a cause of sudden visual loss: a management strategy
Retinal artery occlusion (RAO) is a frequent cause of sudden, painless, monocular visual loss.Many patients with symptomatic RAO also have systemic vascular diseases that may increasethe risk of future ipsilateral hemispheric cerebral vascular events. For healthcare professionalswho assess patients with RAO, knowledge of the possible ocular and systemic causes may notonly improve the patient’s visual prognosis, but may also reduce its associated mortality andmorbidity by encouraging prompt and appropriate referrals.
Cardiovascular risk management: 8 Pharmacotherapy – improving the lipid profile
Epidemiological and clinical research has determined that lipids contribute substantially to cardiovascular disease (CVD) and that modifying the lipid profile has a significant impact on coronary events. These findings are reflected in continuously updated CVD management guidelines, which focus on low-density lipoprotein cholesterol (LDL-C) as the primary therapeutic target. The guidelines have further defined LDL-C levels to which patients should be treated. An individual’s eligibility for treatment, and their LDL-C treatment goal and intensity of therapy is determined by their absolute CVD risk. Lipid abnormalities can be partly modified by lifestyle changes, which are integral to reducing risk for all patients. However, as lipid goals are progressively lowered, many patients will not be able to achieve them using lifestyle changes alone and these patients usually require treatment with lipid-modifying drugs. This article aims to provide practitioners with a concise guide to managing lipids with pharmacotherapy, based on recommendations from six of the most up-to-date clinical practice guidelines for prevention of cardiovascular disease.
The importance of counselling in patients initiated on potentially nephrotoxic drugs
Measurement of renal function in patients starting on angiotensin-converting enzyme (ACE) inhibitors within one week after commencement of treatment or dose adjustment is compulsory, and failure to do so would be negligent.
Pharmacy-based health checks – acceptable and feasible
Pharmacists in the ethnically diverse city of Leicester piloted Healthy Life Checks in inner-city pharmacies, forpeople aged 40-74. Pharmacists conducted checks including blood pressure, weight and glucose measurementand gave lifestyle advice. We present here the findings from semi-structured telephone interviews conductedwith pharmacists and service users.
Cardiovascular risk management: 7 Lifestyle changes to reduce cardiovascular risk
Epidemiological research has clearly established that many risk factors contribute to cardiovascular disease(CVD). Some of them are modifiable, and treatment decisions are based on the level of risk determined by risk assessment. Positive lifestyle changes are crucial to the prevention and management of CVD, and can result in substantial risk reduction. These changes can include smoking cessation interventions, acardioprotective dietary pattern and increased physical activity. However, lifestyle changes are challenging forboth the healthcare professional and the patient, and behavioural counselling and regular follow-ups are often required to overcome barriers, encourage adherence and assist in the achievement of long-term lifestyle goals.This article aims to provide practitioners with a concise guide to the role and impact of lifestyle changesbased on recommendations from six of the most up-to-date clinical practice guidelines for prevention ofcardiovascular disease.
Dietary change post-MI – the key aspect of lifestyle change
Recent research suggests that post-MI patients are not being optimally managed. Awareness and implementation of guideline recommendations could improve outcomes in this patient group.
